​​Systemic third generation allosteric STING agonist CRD3874-SI, a novel immunotherapy, in patients with advanced solid tumors: Results from a single-agent phase I study.

The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA. 2026  

View Abstract

Phase I trial of CRD3874-SI, a systemically administered third generation allosteric STING agonist, in patients with advanced solid tumors

The Annual meeting of the American Society for Cancer Research (AACR), San Diego, CA, 2026

View Abstract

Synthesis and structure-activity evaluation of a series of novel tricyclic STING activators.

 Eur. J. Med. Chem.,2025

View Article

​CRD3874-SI: a novel allosteric STING agonist with high systemic tolerability

Immunotherapy of Cancer Conference, Munich, Germany. 2024 

View Abstract

​Systemic delivery of novel, allosteric STING agonist CRD3874-SI leads to robust anti-cancer activity by generating pro-inflammatory Type I IFN signals while blocking proton channel mediated toxicity

The Society for Immunotherapy of Cancer (SITC), San Diego, USA, 2023

View Abstract

​Intravenous administration of the small molecule STING agonist CRD5500 elicits potent anti-tumor immune responses in cold tumors

AACR Annual Meeting, New Orleans, Louisiana, USA, 2022 

View Abstract

The discovery of potent small molecule cyclic urea activators of STING

Eur. J. Med. Chem.,2022

View Article

The discovery of potent small molecule activators of human STING 

Eur. J. Med. Chem.,2020

View Article

​G10 is a direct activator of human STING

PLOS One, 2020

View Article

​​CRD5500: A versatile small molecule STING agonist amenable to bioconjugation as an ADC

AACR Annual Meeting, Atlanta, GA, USA, 2019     

View Abstract

​Novel small-molecule human STING agonists generate robust Type I interferon responses in tumors

​

AACR conference on Tumor Immunology and Immunotherapy in Boston, MA, USA, 2017

View Abstract